John Morphy at Eli Lilly to Speak at Protein Kinases and Drug Design Conference Nov 8-9, 2012 Boston
John Richard Morphy, Senior Research Advisor of Medicinal Chemistry at Eli Lilly will give a presentation on "Designing Selectively Non-selective Drugs" at the Protein Kinases and Drug Design conference taking place on Nov 8-9, 2012 in Boston, MA.
- San Diego, CA (1888PressRelease) October 09, 2012 - Given the inherent complexity of biological systems, it has become increasingly well recognized that modulating multiple biological targets in parallel can be beneficial for treating complex, multigenic diseases, such as cancer, inflammation, psychiatric disorders and neurodegeneration. Dr. Morphy will use examples from kinases and other relevant target families to illustrate how different approaches to lead generation can be utilized. He will also address the challenges faced by medicinal chemists in lead optimization including the need to appropriately balance the activity profile and obtain acceptable global selectivity, whilst attaining the physicochemical and pharmacokinetic properties of an oral drug.
Richard Morphy joined Celltech Ltd. in Slough (U.K.) as a medicinal chemist working on a variety of oncology and inflammation projects. Subsequently he moved to Organon Laboratories in Scotland where he was a section head in the medicinal chemistry department until 2011, through the mergers of Organon with Schering-Plough in 2007 and Merck in 2009. His focus on complex disorders lead to a keen interest and expertise in the field of multi-target drug discovery. Since last year, he has been working as a senior research advisor in the neuroscience area at the Lilly Research Centre in Windlesham, Surrey, UK.
GTC's Protein Kinases and Drug Design conference, one of two parallel tracks of the Cancer Summit - Novel Approaches to Drug Discovery on November 8-9 in Boston, MA, brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on drug design and development, selective and non-selective kinases inhibitors, hit and target identification, oncology kinases and inhibitors, and other kinases targets. Experts will also share their positive and negative experiences on how predictive preclinical models are with clinical efficacy and toxicology.
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam